Hikma Pharmaceuticals Plc EGM Statement (6239P)

TIDMHIK

RNS Number : 6239P

Hikma Pharmaceuticals Plc

19 February 2016

Hikma Pharmaceuticals PLC

Voting Results of Extraordinary General Meeting

London, 19 February 2016 - Hikma Pharmaceuticals PLC ("Hikma" or the "Company") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, announced on 28 July 2015 that it had agreed terms to acquire Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc. from Boehringer Ingelheim (the "Acquisition").

The Company is pleased to announce that, at the General Meeting held today, the resolutions (the "Resolutions") in respect of the Acquisition were decided on a poll and passed as ordinary resolutions. Details of the Resolutions were set out in the combined prospectus and circular published on 22 January 2016 and posted to shareholders on 25 January 2016 (the "Prospectus") and the supplementary prospectus and circular which was published and sent to shareholders on 11 February 2016. Completion of the Acquisition is expected to take place on 29 February 2016.

The total number of votes cast on the poll for each resolution is set out below.

 
          Resolution               For               Against         Votes        Total 
                                                                    withheld      votes 
                                                                                   cast 
---  -------------------  ---------------------  ---------------  ----------  ------------ 
                              Votes        %      Votes      % 
---  -------------------  ------------  -------  -------  ------  ----------  ------------ 
      Approving 
 1.    the transaction     157,068,100   99.98%   31,346   0.02%    491,344    157,099,446 
---  -------------------  ------------  -------  -------  ------  ----------  ------------ 
      Granting 
       the Directors 
       authority 
       to allot 
       the Consideration 
 2.    Shares              157,078,102   99.99%   21,344   0.01%    491,344    157,099,446 
---  -------------------  ------------  -------  -------  ------  ----------  ------------ 
      Approving 
       the off-market 
       purchase 
       contract 
       and off-market 
       purchase 
       by the 
       Company 
       of its 
 3.    own shares          157,049,321   99.97%   50,341   0.03%    491,128    157,099,662 
---  -------------------  ------------  -------  -------  ------  ----------  ------------

Notes:

As at 19 February 2016, the Company's issued share capital was 199,385,501 ordinary shares of 10 pence each.

1. Votes withheld are not votes under English law and so have not been included in the calculation of the votes case "For" or "Against" the Resolution.

2. Percentages are expressed as a proportion of the total votes cast and have been rounded to two decimal places.

Completion of the Acquisition remains subject to the satisfaction or waiver of certain other conditions, including the expiration of any HSR Act antitrust waiting period, set out in Part I of the Prospectus.

Capitalised terms used in this announcement have the meanings given to them in the Prospectus.

This announcement is made pursuant to the requirements of Listing Rule 9.6.18R. In accordance with Listing Rule 9.6.2R, two copies of the Resolutions will shortly be submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.couk/uk/NSM.

The results of the General Meeting will shortly be available on the Company's website at www.hikma.com.

For further information please contact:

Hikma Pharmaceuticals PLC

Peter Speirs +44 20 7399 2670

Company Secretary

Susan Ringdal +44 20 7399 2670

VP for Investor Relations and Strategy

FTI Consulting

   Ben Atwell/ Matthew Cole                                                         +44 20 3727 1000

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

REGSFSFEUFMSEIE

(END) Dow Jones Newswires

February 19, 2016 07:55 ET (12:55 GMT)

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024